tbuckley/cabot-search huggingface dataset:
Magnetic Nanoparticles for Efficient Delivery of Growth Factors: Stimulation of Peripheral Nerve Regeneration
Authors: Martina Giannaccini, M. Pilar Calatayud, Andrea Poggetti, Silvia Corbianco, Michela Novelli, Melania Paoli, Pietro Battistini, Maura Castagna, Luciana Dente, Paolo Parchi, Michele Lisanti, Gabriella Cavallini, Concepción Junquera, Gerardo F. Goya, Vittoria Raffa
Journal: Advanced Healthcare Materials (2017)

The only clinically approved alternative to autografts for treating large peripheral nerve injuries is the use of synthetic nerve guidance conduits (NGCs), which provide physical guidance to the regenerating stump and limit scar tissue infiltration at the injury site. Several lines of evidence suggest that a potential future strategy is to combine NGCs with cellular or molecular therapies to deliver growth factors that sustain the regeneration process. However, growth factors are expensive and have a very short half-life; thus, the combination approach has not been successful. In the present paper, we proposed the immobilization of growth factors (GFs) on magnetic nanoparticles (MNPs) for the time- and space-controlled release of GFs inside the NGC. We tested the particles in a rat model of a peripheral nerve lesion. Our results revealed that the injection of a cocktail of MNPs functionalized with nerve growth factor (NGF) and with vascular endothelial growth factor (VEGF) strongly accelerate the regeneration process and the recovery of motor function compared to that obtained using the free factors. Additionally, we found that injecting MNPs in the NGC is safe and does not impair the regeneration process, and the MNPs remain in the conduit for weeks.
High Circulating CD34 Cells, Dacrocytes, Clonal Hematopoiesis, and JAK 2 Mutation Differentiate Secondary Myelofibrosis Associated with Pulmonary Hypertension from Myelofibrosis with Myeloid Metaplasia.
Authors: Uday Popat, Enli Liu, Yongli Guan, Josef T. Prchal
Journal: Blood (2005)
A Tissue-Specific Transcriptional Element for C/ebpa Is Required for HSC Maintenance and Neutrophil Development
Authors: Roberto Avellino, Marije Havermans, Claudia Erpelinck, Mathijs Sanders, Stefan Groeschel, Harmen Vandewerken, Remco M. Hoogenboezem, Elwin Rombouts, Kirsten Van Lom, Paulette Van Strien, Hans De Looper, Claudia Christine Gebhard, Michael Rehli, Dominik Beck, Julie A.I. Thoms, Stefan Erkeland, Ivo Touw, John E. Pimanda, Eric JM Bindels, Ruud Delwel
Journal: Blood (2015)
A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.
Authors: Andres Forero-Torres, Nancy L Bartlett, Sunita D Nasta, Donald Northfelt, Anne Beaven, Han Myint, Nancy C Whiting, Jonathan G Drachman, Craig H Moskowitz
Journal: Blood (2009)
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia
Authors: Z Chen, L J Medeiros, H M Kantajian, L Zheng, Z Gong, K P Patel, H Xiong, W Wang, J E Cortes, S Hu
Journal: Blood Cancer Journal (2017)

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia
Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells
Authors: Tomer Itkin, Shiri Gur Cohen, Joel A. Spencer, Amir Schajnovitz, Saravana K. Ramasamy, Anjali P. Kusumbe, Yookyung Jung, Guy Ledergor, Idan Milo, Michael Gustave Poulos, Maria Garcia Fernandez, Alexander Kalinkovich, Aya Ludin, Orit Kollet, Guy Shakhar, Simon Mendez-Ferrer, Jason M. Butler, Shahin Rafii, Ralf H. Adams, David T. Scadden, Charles P. Lin, Tsvee Lapidot
Journal: Blood (2015)
Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy
Authors: Annika Nelde, Juliane S Stickel, Daniel Johannes Kowalewski, Oliver Olaf Wolz, Lothar Kanz, Anton W. Langerak, Alice F. Muggen, Irina Bonzheim, Falko Fend, Hans-Georg Rammensee, Stefan Stevanovic, Alexander N.R. Weber
Journal: Blood (2015)
A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial
Authors: Nigel H. Russell, Robert K Hills, Sylvie Freeman, Steven Knapper, Lars Kjeldsen, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, Alan K. Burnett
Journal: Blood (2015)
Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.
Authors: Kathrine Hannestad, Thomas Stauffer Larsen, Torben Mourits Andersen, Niels Aage Toeffner Clausen, Per Boye Hansen, Bjarne Anker Jensen, Henrik Sverre Birgens, Hans Carl Hasselbalch
Journal: Blood (2007)
Quality of care delivered by general internists in US hospitals who graduated from foreign versus US medical schools: observational study
Authors: Yusuke Tsugawa, Anupam B Jena, E John Orav, Ashish K Jha
Journal: BMJ (2017)

To determine whether patient outcomes differ between general internists who graduated from a medical school outside the United States and those who graduated from a US medical school. Observational study. Medicare, USA. 20% national sample of data for Medicare fee-for-service beneficiaries aged 65 years or older admitted to hospital with a medical condition in 2011-14 and treated by international or US medical graduates who were general internists. The study sample for mortality analysis included 1 215 490 admissions to the hospital treated by 44 227 general internists. Patients' 30 day mortality and readmission rates, and costs of care per hospital admission, with adjustment for patient and physician characteristics and hospital fixed effects (effectively comparing physicians within the same hospital). As a sensitivity analysis, we focused on physicians who specialize in the care of patients admitted to hospital ("hospitalists"), who typically work in shifts and whose patients are plausibly quasi-randomized based on the physicians' work schedules. Compared with patients treated by US graduates, patients treated by international graduates had slightly more chronic conditions. After adjustment for patient and physician characteristics and hospital fixed effects, patients treated by international graduates had lower mortality (adjusted mortality 11.2% v 11.6%; adjusted odds ratio 0.95, 95% confidence interval 0.93 to 0.96; P<0.001) and slightly higher costs of care per admission (adjusted costs $1145 (£950; €1080) v $1098; adjusted difference $47, 95% confidence interval $39 to $55, P<0.001). Readmission rates did not differ between the two types of graduates. Similar differences in patient outcomes were observed among hospitalists. Differences in patient mortality were not explained by differences in length of stay, spending level, or discharge location. Data on older Medicare patients admitted to hospital in the US showed that patients treated by international graduates had lower mortality than patients cared for by US graduates.
Frequency of HCV infection in renal cell carcinoma patients.
Authors: B. Budakoglu, S. Aksoy, C. Arslan, U. Uyeturk, N. A. Babacan, M. F. Ozcan, R. Yildiz, B. B. Oven, N. Ozdemir, O. Dizdar, S. Buyukberber, M. B. Akinci, I. Turker, O. B. Oksuzoglu, M. K. Altundag, N. Zengin
Journal: Journal of Clinical Oncology (2011)

e12004 Background: Chronic infections with hepatitis C virus (HCV) are frequently pronounced in the etiology of malignancies especially in hepatocellular carcinoma. The association between HCV and risk of renal cell carcinoma (RCC) development has been stated recently. Methods: The authors retrospectively evaluated hepatitis serology for HCV and HBV in patients who had RCC diagnosis between 2005 and 2010 in 6 oncology centers. Control group was also included from the published 3 different studies that hepatitis serology studied in healthy people that has been living in the same geographical regions. Results: Histologically confirmed 903 RCC cases and 5267 healthy subjects were included the study. Median age at diagnosis of RCC was 58 (range: 26 - 89). There was no increase in HCV positivity in RCC patient s compared to healthy control group (1.7% vs 1.5% ; p=0.77). Frequency of HBsAg positivity was 4.4% and 4.1% in RCC and control groups, respectively (p=0.65). Conclusions: There is no increase in the frequency of HCV and HBsAg positivity in RCC patients. HCV positivity was not different from the healthy people.
Regulation of Protein Disulfide Isomerase By S-Nitrosylation Controls Its Function during Thrombus Formation
Authors: Roelof H Bekendam, Gopal Srila, Pavan K Bendapudi, James R Dilks, Lin Lin, Sheryl Bowley, Jack Stopa, Mingdong Huang, Bruce Furie, Kevin Croce, Robert Flaumenhaft
Journal: Blood (2014)
Telomere Biology Gene Mutation and Transplant Outcome in Patients with Dyskeratosis Congenita
Authors: Fernanda Gutierrez-Rodrigues, Gustavo Borges, Raquel M Alves-Paiva, Bárbara A Santana-Lemos, Samantha Nichele, Lisandro L Ribeiro, Michel Michels De Oliveira, Larissa A Medeiros, Gisele Loth, Ricardo Pasquini, Carmem Maria Sales Bonfim, Rodrigo T. Calado
Journal: Blood (2015)
Peripheral Blood, Cord Blood and Bone Marrow Cells Sorted into SP+, CD34+ and SP− Cells Are Distinct in Their ABCG2 and MDR1 Expression Levels, Which Are Most Increased in SP+ Cells and Substantially Decline after In Vitro Culture and Terminal Cell Differentiation.
Authors: Martina Kleber, Rebecca Storz, Y. Guo, Dagmar Wider, Gabriele Ihorst, Monika Engelhardt
Journal: Blood (2006)
Clinical Significance of High C-MYC and Low MYCBP2 Expression and Their Association with Ikaros Dysfunction in Adult Acute Lymphoblastic Leukemia
Authors: Zheng Ge, Xing Guo, Jianyong Li, Melanie Hartman, Yuka Imamura Kawasawa, Sinisa Dovat, Chunhua Song
Journal: Blood (2015)
The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide
Authors: Tzu-Fei Wang, Mark Fiala, Rohan Ahluwalia, Kathryn Trinkaus, Caitlin Moliske, Doug Cox, Matthew Jaenicke, Keith Stockerl-Goldstein, Tanya Wildes, Kenneth R. Carson, Michael H. Tomasson, Ravi Vij
Journal: Blood (2012)
Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization.
Authors: Frank P. Kroschinsky, Eberhard Schleyer, Kristina Hoelig, Uta Oelschlaegel, Rainer Ordemann, Kirsten Poppe-Thiede, Markus A. Schaich, Claudia Rutt, Gerhard Ehninger
Journal: Blood (2005)
Defective Neo-Antigen Response to Keyhole Limpet Hemocyanin (KLH) Vaccines in Patients after Hematopoietic Cell Transplantation.
Authors: Jeffrey S. Miller, Julie Curtsinger, Kirsten Malvey, Susan K. Fautsch, Arkadiusz Dudek, Bruce R. Blazar, Angela Panoskaltsis-Mortari
Journal: Blood (2004)
Low-Dose Alemtuzumab as Treatment for Pre-Treated CLL Patients. Evaluation of Response Rate, CMV Disease and Immune Recovery.
Authors: Luca Laurenti, Michela Tarnani, Paola Piccioni, Dimitar Efremov, Patrizia Chiusolo, Alessia Fiorini, Mariagrazia Garzia, Gina Zini, Mariangela Palladino, Silvia Bellesi, Carlo Rumi, Simona Sica, Giuseppe Leone
Journal: Blood (2004)
Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma &amp; MDS.
Authors: Carla M. Van Bennekom, Gregory A. Abel, Richard M. Stone, Kenneth C. Anderson, Noopur Raje, David W. Kaufman
Journal: Blood (2007)
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
Authors: Malachi Griffith, Nicholas C Spies, Kilannin Krysiak, Joshua F McMichael, Adam C Coffman, Arpad M Danos, Benjamin J Ainscough, Cody A Ramirez, Damian T Rieke, Lynzey Kujan, Erica K Barnell, Alex H Wagner, Zachary L Skidmore, Amber Wollam, Connor J Liu, Martin R Jones, Rachel L Bilski, Robert Lesurf, Yan-Yang Feng, Nakul M Shah, Melika Bonakdar, Lee Trani, Matthew Matlock, Avinash Ramu, Katie M Campbell, Gregory C Spies, Aaron P Graubert, Karthik Gangavarapu, James M Eldred, David E Larson, Jason R Walker, Benjamin M Good, Chunlei Wu, Andrew I Su, Rodrigo Dienstmann, Adam A Margolin, David Tamborero, Nuria Lopez-Bigas, Steven J M Jones, Ron Bose, David H Spencer, Lukas D Wartman, Richard K Wilson, Elaine R Mardis, Obi L Griffith
Journal: Nature Genetics (2017)
Epoetin Alfa inhibits stabilization and transcriptional activity of HIF-1α in ovarian cancer cells.
Authors: Sarah A. Hale, Cheung Wong, Karen M. Lounsbury
Journal: Cancer Research (2004)

3585   Cancerous tumors adjust their signaling pathways to facilitate survival in a hypoxic environment. Hypoxia inducible factor-1α (HIF-1α) is a transcription factor that is stabilized in hypoxic situations and induces transcription of target genes such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO). We have previously shown increases in both HIF-1α and VEGF in advanced stages of ovarian cancer. Although EPO may stimulate proliferation of tumors through growth factor pathways, some studies have shown slightly improved response to chemotherapy with exogenous administration of EPO (Epoetin Alfa). In this study, we used cultured human ovarian cancer cells (SK-OV-3) to investigate the hypothesis that exogenous Epoetin Alfa will exert negative feedback regulation of HIF-1α and will consequently reduce VEGF transcription in ovarian cancer cells. Expression of EPO-receptor (EPO-R) in SK-OV-3 cells was demonstrated by RT-PCR and immunofluorescence (IMF). To measure the effect of Epoetin Alfa on HIF-1α, cells were exposed to hypoxia with or without Epoetin Alfa for 16 hrs and HIF-1α levels were determined by immunoblot and IMF. Epoetin Alfa had no effect on HIF-1α levels under normoxic conditions. However, Epoetin Alfa significantly inhibited hypoxia-induced HIF-1α expression in a dose-dependent fashion. To determine if the observed loss of HIF-1α also resulted in loss of VEGF transcription, SK-OV-3 cells were treated for 48 hrs in hypoxia with or without Epoetin Alfa and VEGF transcription was evaluated using RT-PCR. Epoetin Alfa significantly reduced hypoxia-induced VEGF transcription to near basal levels. The effect of Epoetin Alfa on HIF-1α was not restricted to ovarian cancer cells as induction of HIF-1α by hypoxia was also inhibited by Epoetin Alfa in MCF-7 breast cancer cells. These studies indicate that Epoetin Alfa treatment not only inhibits HIF-1α levels induced by hypoxia, but also inhibits synthesis of VEGF, a potent angiogenic growth factor and downstream target gene of HIF-1α. These data broaden the potential clinical applications of Epoetin Alfa as an anti-angiogenic chemotherapy agent and may explain why patients taking Epoetin Alfa show improved response to chemotherapy. Future directions include characterizing the molecular target of Epoetin Alfa in the HIF-1α signaling pathway and developing a mouse model to test the ability of Epoetin Alfa to alter tumor size and angiogenesis  in vivo . This research was supported by Ortho Biotech #PR03-27-029.
Lymphocyte Recovery Kinetics in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation
Authors: David Jared Kobulnicky, Roy T Sabo, Ali S Shubar Ali, Catherine H. Roberts, Allison F Scalora, Kristen M Kobulnicky, Shiyu Song, William B. Clark, Harold M. Chung, John M. McCarty, Michael C. Neale, Amir A. Toor
Journal: Blood (2015)
Effect of arousal on perception as studied through the lens of the motor correlates of sexual arousal
Authors: Harold Mouras
Journal: Behavioral and Brain Sciences (2016)

Abstract The study of sexual arousal is at the interface of affective and social neurosciences. Recent results regarding the motor correlates of sexual arousal demonstrating an early freezing response are in perfect accordance with the GANE (glutamate amplifies noradrenergic effects) model's sustaining the double role of the arousal dimension on emotional processing.
The distinction between perception and judgment, if there is one, is not clear and intuitive
Authors: Andreas Keller
Journal: Behavioral and Brain Sciences (2016)

Abstract Firestone &amp; Scholl (F&amp;S) consider the distinction between judgment and perception to be clear and intuitive. Their intuition is based on considerations about visual perception. That such a distinction is clear, or even existent, is less obvious in nonvisual modalities. Failing to distinguish between perception and judgment is therefore not a flaw in investigating top-down effects of cognition on perception, as the authors suggest. Instead, it is the result of considering the variety of human perception.
BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia
Authors: Christian Hurtz, Cihangir Duy, Leandro Cerchietti, Katerina Chatzi, Eugene Park, Lars Klemm, Yong-mi Kim, Michael Kahn, Melanie Braig, Martin C. Muller, Andreas Hochhaus, B. Hilda Ye, Ari M. Melnick, Markus Muschen
Journal: Blood (2010)
On the neural implausibility of the modular mind: Evidence for distributed construction dissolves boundaries between perception, cognition, and emotion
Authors: Leor M. Hackel, Grace M. Larson, Jeffrey D. Bowen, Gaven A. Ehrlich, Thomas C. Mann, Brianna Middlewood, Ian D. Roberts, Julie Eyink, Janell C. Fetterolf, Fausto Gonzalez, Carlos O. Garrido, Jinhyung Kim, Thomas C. O'Brien, Ellen E. O'Malley, Batja Mesquita, Lisa Feldman Barrett
Journal: Behavioral and Brain Sciences (2016)

Abstract Firestone &amp; Scholl (F&amp;S) rely on three problematic assumptions about the mind (modularity, reflexiveness, and context-insensitivity) to argue cognition does not fundamentally influence perception. We highlight evidence indicating that perception, cognition, and emotion are constructed through overlapping, distributed brain networks characterized by top-down activity and context-sensitivity. This evidence undermines F&amp;S's ability to generalize from case studies to the nature of perception.
Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Authors: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir
Journal: Journal of Clinical Oncology (2011)

8017 Background: SAR3419 (huB4-DM4) is an antibody–drug conjugate composed of a humanized IgG1 monoclonal antibody, huB4, which specifically targets the CD19 antigen, conjugated through a disulfide link to the maytansinoid derivative DM4, a potent tubulin inhibitor. After binding to the CD19 antigen, SAR3419 undergoes internalization and intracellular release of DM4. Methods: In this phase I/II study SAR3419 was administered by intravenous infusion, weekly for 8 to 12 doses, to pts with relapsed/refractory B-cell NHL expressing CD19. Results: Forty-four pts were enrolled at 7 dose levels from 10 to 70 mg/m². Main histologies were follicular (18; 41%) and diffuse large B-cell (17; 39%). Median number of prior regimens was 3 (1-8) and 19 pts had received prior transplantation. Twenty-eight pts were enrolled in the dose escalation part. Of 6 pts at 70 mg/m², 1 pt had a protocol defined dose limiting toxicity of neutropenia and 2 pts had grade 2 significant toxicities with late onset: blurred vision associated with corneal deposits and left bundle branch block. The maximum tolerated dose (MTD) was defined at 55 mg/m². Of 22 pts at the MTD, 4 pts had related reversible grade 3-4 toxicities after 6-8 doses: optic neuropathy, paraesthesia, neutropenia and thrombocytopenia. Of 38 pts at doses of 20 mg/m² or higher, 12 (32%) pts achieved an objective response including 6 CR/CRu, with no obvious dose effect. Of 22 pts at the MTD (55 mg/m²), 8 (36%) had a response, including 3 CR/CRu. Of 9 pts evaluable for response duration (RD), 4 pts had a RD ranging from 6 to at least 12 months. Conclusions: These results demonstrate evidence of clinical activity and manageable safety, without significant myelosuppression. A modified schedule (4 weekly doses of 55 mg/m² followed by every 2 weeks dosing) is under evaluation. Updated clinical and pharmacokinetic data will be presented.
A Human Bone Marrow-Derived Stromal Cell Population with Hemogenic Potential
Authors: Saloomeh Mokhtari, Evan Joseph Colletti, Chad Sanada, Zanetta S. Lamar, Paul J Simmons, Anthony Atala, Diane S Krause, Esmail D. Zanjani, Christopher D Porada, Graca Almeida-Porada
Journal: Blood (2015)
QOL-04IS THE OUTCOME OF GLIOBLASTOMA MULTIFORME (GBM) AFFECTED BY SOCIOECONOMIC FACTORS?
Authors: Anuradha Belur, Arun Kumar Raajasekar, Bernadine Donahue, Jim Huang, Peter Homel, Yiqing Xu
Journal: Neuro-Oncology (2015)

Patients diagnosed with GBM RPA class IV and V have median survival (MS) of 15 and 10 months respectively after standard adjuvant chemoradiation (CRT) in randomized trials. We evaluated unfavorable socioeconomic factors (SEF) in patients treated in the community and its effect on the outcome. METHODS: Retrospective analysis of GBM patients treated at the Maimonides Hospital between 1/2008-5/2014. Six unfavorable SEFs were selected: (1) Medicaid Insurance (2) non-English speaking (3) no family at first visit (4) or at last visit, (5) need of home health aide (HHA) (6) need for transportation. Outcomes measure included MS, completion of CRT and adjuvant Temozolomide (TMZ). RESULTS: 58 patients (32 M, 26F) with median age of 64 (range 29 - 85) were identified; 16 were older than 70. 34 (58%) had Medicaid, 22 (37%) were non-English speaking, 10 (17%) required an HHA. Median number of SEFs was 2 (range 0 - 6), 12 patients (36%) had ≥3 SEFs. 14 patients (24 %) were RPA class IV and 44 (76 %) were class V, MS was 12 m (95% CI, 10.2 - 13.8) and 11 m (95% CI, 6.9 - 15.1) respectively. 54 (93%) patients completed CRT and 21(36%) completed adjuvant TMZ. In univariate analysis, the SEF of need of HHA, showed an adverse effect vs those with no HHA. MS was 7 m versus 13 m (p= 0.035), and the completion rate for CRT was 72 % vs 97% (p= 0.019). Sum of SEFs did not affect any outcome. CONCLUSIONS: Our patients with GBM had overall survival comparable to that in the randomized trials. Only SEF which adversely affected the outcomes was those patients who needed HHA. Necessity of HHA indicates worse physical function and poor family support.
Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.
Authors: Thomas C. Shea, Jeffrey Johnston, William Walsh, Sherif Farag, John McCarty, Asad Bashey, Luis Isola, Marc Stewart, Michael Kelly, Kouros Owzar, Charles Linker
Journal: Blood (2007)
P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy
Authors: Pere Gascón, Rajnish Nagarkar, Martin Šmakal, Kostas Syrigos, Carlos H. Barrios, Jesús Cárdenas Sánchez, Li Zhang, David H. Henry, Alex Fleishman, Cisio De Oliveira Brandao
Journal: Journal of Thoracic Oncology (2016)
Long-Acting Reversible Contraception
Authors: Kathryn M. Curtis, Jeffrey F. Peipert
Journal: New England Journal of Medicine (2017)

This article reviews methods of long-acting reversible contraception, including IUDs and hormonal implants. These methods are about 20 times as effective as pills, patches, and rings and are safe for almost all women, including those in a postpartum or postabortion period.
Improving Cardiovascular Health in Diverse Populations
Authors: Anushka Patel, John D. Rutherford
Journal: Circulation (2017)

Anushka Patel is the Chief Scientist, The George Institute for Global Health, Professor of Medicine, University of Sydney and a Cardiologist, at Royal Prince Alfred Hospital, all based in Sydney, Australia. She obtained her MBBS from the University of Queensland, a Master of Science degree in Epidemiology from Harvard University, and her PhD from the University of Sydney.